Filter By Category
Archives
Share on -
DEVEXTINETUG
Generic Name: DEVEXTINETUG
ABSTRACT -
Devextinetug is an investigational chimeric monoclonal antibody designed to bind methamphetamine and reduce central nervous system exposure by peripheral sequestration. A single small-molecule formula is not applicable.
DOSAGE -
- No routine clinical dosage is established for general use.
- Dose, route, infusion schedule, and observation must follow the clinical-trial protocol.
- It should be administered with appropriate behavioral and medical support for substance-use disorders.
SIDE EEFECTS -
- Infusion reactions, headache, fatigue, nausea, fever, chills, or rash may occur.
- Anti-drug antibody formation or altered methamphetamine pharmacokinetics may occur.
- Psychiatric or withdrawal-related symptoms require clinical monitoring.
ALLERGIC REACTIONS -
- Immediate rash, hives, itching, flushing, or generalized skin reaction
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, shortness of breath, or severe dizziness
- Severe hypotension, collapse, or anaphylaxis requires emergency care
- Any suspected allergy should be documented and reported to future healthcare providers
DRUG INTERACTIONS-
- Methamphetamine, stimulants, sympathomimetics, and substance-use treatments require careful clinical review.
- Other biologics or immunosuppressants may alter immune response.
- Patients should report all prescribed and non-prescribed substances.
PREAUTONS–
- Use under addiction-medicine and clinical-trial supervision.
- Monitor mental status, cardiovascular status, substance use, hypersensitivity, and immunogenicity.
- Pregnancy and lactation require specialist review.
WARNINGS –
- Chest pain, severe agitation, psychosis, anaphylaxis, or overdose symptoms require emergency care.
- Investigational efficacy and safety are not fully established.
- Keep out of reach of children.
Share on -
. Developed by